Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Dr. Reddy's Laboratories Ltd ADR
(NY:
RDY
)
69.45
+0.70 (+1.02%)
Streaming Delayed Price
Updated: 2:59 PM EDT, Jun 5, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Headline News about Dr. Reddy's Laboratories Ltd ADR
< Previous
1
2
3
4
Next >
India Stocks Rally On Modi Election Wave. This Indian Bank Stock Hits High.
June 03, 2024
Exit polls forecast a landslide win and third consecutive term for Prime Minister Narendra Modi in India's general elections.
Via
Investor's Business Daily
RDY Stock Earnings: Dr Reddy’s Laboratories Beats EPS, Misses Revenue for Q4 2024
May 07, 2024
RDY stock results show that Dr Reddy's Laboratories beat analyst estimates for earnings per share but missed on revenue for the fourth quarter of 2024.
Via
InvestorPlace
Global Access to Weight-Loss Treatments: Indian Pharma Giants Eye Affordable Wegovy Alternatives Amid Rising Demand
February 22, 2024
Indian pharmaceutical giants, including Sun Pharma and Cipla, seize the opportunity to develop affordable versions of Novo Nordisk's Wegovy weight-loss treatment. With patents set to expire by...
Via
Benzinga
Topics
Intellectual Property
Exposures
Intellectual Property
Dr Reddy's Laboratories: Q3 Earnings Insights
January 30, 2024
Via
Benzinga
Why Quality Investors Should Delve into DR. REDDY'S LABORATORIES-ADR (NYSE:RDY) for Investment Opportunities.
October 24, 2023
Reasonable Growth, Debt Levels, and a High ROIC Make DR. REDDY'S LABORATORIES-ADR (NYSE:RDY) Appealing to Quality Investors.
Via
Chartmill
Is NYSE:RDY suited for quality investing?
September 14, 2023
Exploring DR. REDDY'S LABORATORIES-ADR (NYSE:RDY)'s quality characteristics.
Via
Chartmill
Should you consider NYSE:RDY for quality investing?
August 21, 2023
DR. REDDY'S LABORATORIES-ADR (NYSE:RDY) may be suited for quality investing, we'll explore why in this article.
Via
Chartmill
Chart Of The Day: What's Cooking At Dr. Reddy's Lab
July 28, 2023
100% technical buy signals 12 new highs and up 10.76% in the last month 38.40+ Weighted Alpha
Via
Talk Markets
Intercept Settles Ocaliva Litigation With Reddy's Lab
August 17, 2022
Via
Benzinga
Top 5 Health Care Stocks That May Fall Off A Cliff
August 23, 2023
The most overbought stocks in the health care sector presents an opportunity to go short on these overvalued companies.
Via
Benzinga
Why Are Journey Medical Shares Trading Lower Today?
July 11, 2023
Journey Medical Corporation (NASDAQ: DERM) shares are trading lower after the company announced topline results from the two Phase 3 trials, evaluating Minocycline Hydrochloride Modified Release...
Via
Benzinga
Why Are Journey Medical Shares Trading Higher Today
June 13, 2023
Journey Medical Corporation (NASDAQ: DERM) announced topline data from the Phase 1 clinical trial assessing the impact of DFD-29 on the
Via
Benzinga
The 3 Most Undervalued Value Stocks to Buy in June 2023
June 04, 2023
One positive aspect about broader market challenges is the rising opportunity in the best undervalued value stocks for June.
Via
InvestorPlace
Week In Review: BlissBio Announces Potential $2 Billion Deal With Eisai For HER2 ADC
May 13, 2023
Bliss Biopharma may out-license global rights for its HER2 ADC to Eisai Pharma in a deal with a potential value of $2 billion. Also, Junshi Bio out-licensed regional rights for its anti-PD-1 mAb to Dr....
Via
Talk Markets
India Based Pharma Companies In Race To Buy Athenex, Shares Surge
August 05, 2022
Via
Benzinga
Eton Pharma Shares Tick Higher After Offloading Hospital Products
June 24, 2022
Via
Benzinga
Why Aditxt Shares Are Surging Today
April 20, 2023
Aditxt, Inc. (NASDAQ: ADTX) stock is surging Thursday as it expands its portfolio to include innovative therapies for infectious diseases.
Via
Benzinga
Coya Therapeutics Enters First-Of-Its-Kind Partnership With Multi-Billion Dollar Drug Company — Why This Is a Major Moment For Drug Development
March 23, 2023
Coya Therapeutics Enters First-Of-Its-Kind Partnership With Multi-Billion Dollar Drug Company — Why This Is a Major Moment For Drug Development
Via
News Direct
Coya Therapeutics Enters First-Of-Its-Kind Partnership With Multi-Billion Dollar Drug Company — Why This Is A Major Moment For Drug Development
March 22, 2023
Houston-based Coya Therapeutics (NASDAQ: COYA) has entered into a partnership with Dr. Reddy’s Laboratories Ltd. (NYSE: RDY), a world-leading pharmaceutical company based in India.
Via
Benzinga
Houston-Based Coya Therapeutics Partners With Multi-Billion Dollar Global Drug Company Dr. Reddy’s Laboratories To License and Commercialize COYA 302
March 21, 2023
Houston-Based Coya Therapeutics Partners With Multi-Billion Dollar Global Drug Company Dr. Reddy’s Laboratories To License and Commercialize COYA 302
Via
News Direct
Houston-Based Coya Therapeutics Partners With Multi-Billion Dollar Global Drug Company Dr. Reddy's Laboratories To License And Commercialize COYA 302
March 20, 2023
Coya Therapeutics, Inc. (NASDAQ: COYA) recently announced a worldwide agreement with Dr. Reddy’s Laboratories Limited.
Via
Benzinga
Dr. Reddy's Seeks Gaining Foothold In Women's Health Via Mayne Pharma's U.S. Generic Prescription Deal
February 27, 2023
Via
Benzinga
The 3 Most Undervalued Stocks in India for Your February Buy List
January 31, 2023
These are a few of the top undervalued stocks in India, providing investors with exposure to strong growth outlooks in the coming years.
Via
InvestorPlace
Intercept Surges To Four-Month High After Staving Off Amneal's Generic For 11 Years
January 25, 2023
Intercept entered a deal with Amneal, likely lining up a series of new settlements.
Via
Investor's Business Daily
Journey Medical Touts Positive PK Data For Bacterial Infection Candidate
December 20, 2022
Via
Benzinga
Novartis Fails To Prevent Generic Competition For Its Blockbuster Multiple Sclerosis Drug
October 14, 2022
The U.S. Supreme Court rejected Novartis AG's (NYSE: NVS) effort to block the launch of generic versions of its multiple sclerosis drug Gilenya.
Via
Benzinga
Biotech Daily: Thumbs Down For Acadia's Antipsychotic Drug, Akebia Fails COVID-19 Study, Kazia's Encouraging Data In Brain Metastases
August 05, 2022
Here's a roundup of top developments in the biotech space over the last 24 hours:
Via
Benzinga
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Friday
August 05, 2022
Good morning! We're starting off the last day of trading this week with a breakdown of the biggest pre-market stock movers for Friday!
Via
InvestorPlace
Positive Phase 2 Results Of SciSparc's Cannabinoid-Based Drug Candidate May Offer Some New Hope To Tourette Syndrome Patients
May 25, 2022
This post contains sponsored advertising content. This content is for informational purposes only and is not intended to be investing advice.
Via
Benzinga
European Cannabis Q1 2022 Quarterly Update
April 28, 2022
Just like the United States’ state-by-state movement, Europe is moving country-by-country toward providing access to cannabis.
Via
Talk Markets
< Previous
1
2
3
4
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.